Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8779MR)

This product GTTS-WQ8779MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8779MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14577MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ13098MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ7725MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ10200MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LDP-02
GTTS-WQ15954MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ8461MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ3693MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ6247MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR57
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW